

# Stefano Cascinu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8241530/publications.pdf>

Version: 2024-02-01

705  
papers

20,804  
citations

13827

67  
h-index

20900

115  
g-index

728  
all docs

728  
docs citations

728  
times ranked

25210  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. <i>Journal of Clinical Oncology</i> , 2011, 29, 2011-2019.	0.8	1,713
2	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. <i>Pancreatology</i> , 2015, 15, 8-18.	0.5	404
3	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 2622-2629.	0.8	402
4	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 569-579.	5.1	384
5	Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. <i>Annals of Oncology</i> , 2000, 11, 837-843.	0.6	339
6	Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>Journal of Clinical Oncology</i> , 2002, 20, 3478-3483.	0.8	331
7	Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. <i>Journal of Clinical Oncology</i> , 2007, 25, 3238-3245.	0.8	321
8	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. <i>Annals of Oncology</i> , 2009, 20, 227-230.	0.6	294
9	Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). <i>Annals of Oncology</i> , 2007, 18, 510-517.	0.6	258
10	Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies. <i>Journal of Clinical Oncology</i> , 2004, 22, 4772-4778.	0.8	235
11	The evolving role of microsatellite instability in colorectal cancer: A review. <i>Cancer Treatment Reviews</i> , 2016, 51, 19-26.	3.4	207
12	Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. <i>Journal of Clinical Oncology</i> , 1994, 12, 1058-1062.	0.8	194
13	Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 4000-4000.	0.8	193
14	Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. <i>Journal of Clinical Oncology</i> , 1995, 13, 26-32.	0.8	171
15	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. <i>Annals of Oncology</i> , 2012, 23, 2313-2318.	0.6	170
16	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. <i>Cancer Treatment Reviews</i> , 2015, 41, 114-121.	3.4	161
17	Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. <i>Clinical Cancer Research</i> , 2000, 6, 2803-7.	3.2	155
18	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. <i>Targeted Oncology</i> , 2016, 11, 143-148.	1.7	152

#	ARTICLE	IF	CITATIONS
19	Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. <i>Journal of Clinical Oncology</i> , 2016, 34, 436-442.	0.8	145
20	Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v55-v58.	0.6	134
21	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. <i>Lancet Oncology</i> , The, 2008, 9, 39-44.	5.1	130
22	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). <i>British Journal of Cancer</i> , 2009, 101, 1261-1268.	2.9	130
23	Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1883-1891.	0.8	129
24	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012, 48, 2941-2953.	1.3	129
25	Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. <i>Cancer</i> , 2009, 115, 1544-1554.	2.0	127
26	Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. <i>Journal of the National Cancer Institute</i> , 2008, 100, 388-398.	3.0	123
27	Nuclear Factor-κB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 3930-3935.	0.8	121
28	Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. <i>Annals of Oncology</i> , 2007, 18, 1660-1665.	0.6	116
29	Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. <i>Annals of Oncology</i> , 2003, 14, 1026-1038.	0.6	114
30	Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. <i>European Journal of Cancer Part B, Oral Oncology</i> , 1994, 30, 234-236.	0.9	111
31	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1757-1768.	2.0	110
32	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE study. <i>International Journal of Cancer</i> , 2014, 135, 1247-1256.	2.3	109
33	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. <i>Annals of Oncology</i> , 2012, 23, 2072-2077.	0.6	108
34	Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. <i>International Journal of Surgery</i> , 2018, 51, 120-127.	1.1	106
35	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1533-1539.	0.5	104
36	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 195.	1.1	101

#	ARTICLE	IF	CITATIONS
37	Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.. <i>Journal of Clinical Oncology</i> , 1997, 15, 3313-3319.	0.8	100
38	Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1685-1702.	0.5	100
39	Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2012, 106, 799-804.	2.9	97
40	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 601-607.	3.0	96
41	Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. <i>European Journal of Cancer</i> , 2008, 44, 182-194.	1.3	93
42	Phase II study of paclitaxel in pretreated advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 1998, 9, 307-310.	0.7	91
43	Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. <i>Oncogene</i> , 2002, 21, 8192-8195.	2.6	91
44	Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.. <i>Journal of Clinical Oncology</i> , 1993, 11, 148-151.	0.8	90
45	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. <i>Oncologist</i> , 2019, 24, 185-192.	1.9	89
46	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5369.	1.8	88
47	Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. <i>Annals of Oncology</i> , 2010, 21, 655-661.	0.6	84
48	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. <i>Oncologist</i> , 2014, 19, 966-974.	1.9	84
49	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 271-275.	3.4	84
50	Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2784-2789.	3.2	83
51	A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 1999, 80, 1595-1598.	2.9	81
52	The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. <i>BMC Cancer</i> , 2014, 14, 110.	1.1	80
53	High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 1377-1384.	0.7	80
54	Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. <i>Clinical Cancer Research</i> , 1999, 5, 1996-9.	3.2	80

#	ARTICLE	IF	CITATIONS
55	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 1755-1759.	2.9	79
56	A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. <i>Annals of Oncology</i> , 2000, 11, 1263-1266.	0.6	78
57	Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. <i>British Journal of Cancer</i> , 2008, 98, 143-147.	2.9	78
58	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1641-1645.	1.1	78
59	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. <i>European Journal of Cancer</i> , 2013, 49, 3616-3624.	1.3	78
60	<i>BAP1</i> , <i>PBRM1</i> and <i>SETD2</i> in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 1201-1210.	1.5	78
61	Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1146-1155.	0.5	77
62	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	1.9	77
63	Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. <i>Oncotarget</i> , 2016, 7, 58649-58658.	0.8	76
64	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , 2017, 86, 106-114.	1.3	76
65	Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. <i>Annals of Oncology</i> , 2008, 19, 1293-1298.	0.6	74
66	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. <i>Annals of Surgical Oncology</i> , 2015, 22, 2094-2100.	0.7	72
67	A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. <i>British Journal of Cancer</i> , 1995, 71, 97-101.	2.9	71
68	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. <i>British Journal of Cancer</i> , 2013, 108, 1126-1132.	2.9	71
69	Metabolic alterations in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 767-776.	3.4	71
70	Insulin-like growth factor 1 expression correlates with clinical outcome in KRAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010, 127, 1941-1947.	2.3	67
71	Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019, 25, 3954-3961.	3.2	67
72	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009, 9, 303.	1.1	66

#	ARTICLE	IF	CITATIONS
73	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	0.9	66
74	Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer, 1998, 83, 1917-1922.	2.0	65
75	Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treatment Reviews, 2004, 30, 451-459.	3.4	65
76	Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy. Clinical Cancer Research, 2005, 11, 3778-3783.	3.2	65
77	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	2.9	65
78	Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. British Journal of Cancer, 2013, 109, 1040-1050.	2.9	65
79	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget, 2015, 6, 23323-23341.	0.8	65
80	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	3.5	65
81	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Critical Reviews in Oncology/Hematology, 2015, 96, 81-90.	2.0	64
82	Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Annals of Oncology, 2005, 16, 887-892.	0.6	62
83	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer, 2017, 20, 156-163.	2.7	62
84	State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Critical Reviews in Oncology/Hematology, 2013, 88, 75-86.	2.0	61
85	Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations. Cancers, 2014, 6, 1351-1362.	1.7	61
86	Gastric cancer: Translating novels concepts into clinical practice. Cancer Treatment Reviews, 2019, 79, 101889.	3.4	60
87	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 2004, 90, 1521-1525.	2.9	58
88	Role of STAT3 pathway in genitourinary tumors. Future Science OA, 2015, 1, FSO15.	0.9	58
89	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
90	Mucinous Rectal Adenocarcinoma Can Be Associated to Tumor Downstaging after Preoperative Chemoradiotherapy. Diseases of the Colon and Rectum, 2007, 50, 1594-1603.	0.7	57

#	ARTICLE	IF	CITATIONS
91	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. <i>International Journal of Cancer</i> , 2014, 134, 2772-2777.	2.3	57
92	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. <i>Scientific Reports</i> , 2019, 9, 1788.	1.6	57
93	Prognostic Role of Interleukin-1 <sup>β</sup> Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 2339-2345.	0.8	56
94	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. <i>Molecules</i> , 2014, 19, 6393-6406.	1.7	56
95	Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPCCCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2016, 68, 51-59.	1.3	56
96	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. <i>Targeted Oncology</i> , 2017, 12, 97-109.	1.7	56
97	The Role of HER3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. <i>Oncologist</i> , 2011, 16, 53-60.	1.9	55
98	5-fluorouracil pharmacogenomics: still rocking after all these years?. <i>Pharmacogenomics</i> , 2011, 12, 251-265.	0.6	54
99	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103.	0.9	53
100	Essential Role of Gli Proteins in Glioblastoma Multiforme. <i>Current Protein and Peptide Science</i> , 2013, 14, 133-140.	0.7	53
101	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial); Tj ETQq1 1 01784314 182 /Over	1.7	52
102	The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). <i>Annals of Oncology</i> , 2014, 25, 9-15.	0.6	52
103	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. <i>BioMed Research International</i> , 2014, 2014, 1-12.	0.9	51
104	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. <i>Cell Adhesion and Migration</i> , 2015, 9, 14-21.	1.1	51
105	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	1.3	51
106	HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. <i>Annals of Oncology</i> , 2002, 13, 1398-1403.	0.6	50
107	Hyponatremia in cancer patients: Time for a new approach. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 102, 15-25.	2.0	50
108	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 149-161.	2.0	50

#	ARTICLE	IF	CITATIONS
109	Stevensâ€™Johnson syndrome during nivolumab treatment of NSCLC. <i>Annals of Oncology</i> , 2018, 29, 283-284.	0.6	50
110	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. <i>Cancer Treatment Reviews</i> , 2011, 37, 169-177.	3.4	49
111	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. <i>Targeted Oncology</i> , 2015, 10, 517-522.	1.7	49
112	Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. <i>European Journal of Surgical Oncology</i> , 2017, 43, 613-618.	0.5	49
113	A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. <i>Angiogenesis</i> , 2012, 15, 141-150.	3.7	48
114	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013, 24, 2875-2880.	0.6	48
115	Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. <i>Lung Cancer</i> , 2003, 42, 319-326.	0.9	47
116	Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. <i>Annals of Oncology</i> , 2004, 15, 489-492.	0.6	47
117	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. <i>European Journal of Cancer</i> , 2015, 51, 942-949.	1.3	47
118	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2015, 136, 1-10.	2.3	47
119	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. <i>BMC Cancer</i> , 2017, 17, 137.	1.1	47
120	The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management. <i>PLoS ONE</i> , 2012, 7, e32653.	1.1	47
121	An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. <i>British Journal of Cancer</i> , 2002, 86, 744-749.	2.9	46
122	Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. <i>International Journal of Cancer</i> , 2004, 112, 1010-1014.	2.3	46
123	Performance at Preoperative Stair-Climbing Test Is Associated With Prognosis After Pulmonary Resection in Stage I Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2012, 93, 1796-1800.	0.7	46
124	Advanced Digestive Neuroendocrine Tumors. <i>Pancreas</i> , 2014, 43, 212-218.	0.5	46
125	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 221-231.	3.3	46
126	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. <i>Oncotarget</i> , 2015, 6, 33982-33992.	0.8	46



#	ARTICLE	IF	CITATIONS
127	Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients. <i>Cancer Investigation</i> , 2001, 19, 8-12.	0.6	45
128	Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). <i>Annals of Oncology</i> , 2002, 13, 716-720.	0.6	45
129	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	45
130	Toxicity and Therapeutic Response to Chemotherapy in Patients Aged 70 Years or Older with Advanced Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 371-374.	0.6	45
131	Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. <i>Supportive Care in Cancer</i> , 2015, 23, 3095-3101.	1.0	44
132	Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. <i>Oncotarget</i> , 2016, 7, 26916-26924.	0.8	44
133	A phase II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 1999, 10, 1377-1379.	0.6	43
134	Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy. <i>Annals of Oncology</i> , 2001, 12, 239-244.	0.6	43
135	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials. <i>International Journal of Cancer</i> , 2014, 135, 763-773.	2.3	43
136	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 809-824.	1.9	43
137	Resection-line Involvement in Gastric Cancer Patients Undergoing Curative Resections: Implications for Clinical Management. <i>Japanese Journal of Clinical Oncology</i> , 1999, 29, 291-293.	0.6	42
138	HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. <i>Cancer</i> , 2003, 99, 310-315.	2.0	42
139	Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. <i>Diagnostic Cytopathology</i> , 2003, 28, 142-146.	0.5	42
140	The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. <i>Liver International</i> , 2020, 40, 704-711.	1.9	42
141	Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU). <i>European Journal of Cancer</i> , 1999, 35, S70.	1.3	41
142	Chemotherapy for advanced gastric cancer: across the years for a standard of care. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 797-808.	0.9	41
143	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF- $\kappa$ B activation. <i>British Journal of Cancer</i> , 2008, 98, 71-76.	2.9	41
144	Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. <i>Cancer Treatment Reviews</i> , 2015, 41, 569-576.	3.4	41

#	ARTICLE	IF	CITATIONS
145	Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. <i>British Journal of Cancer</i> , 2006, 95, 445-449.	2.9	40
146	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. <i>Digestive and Liver Disease</i> , 2014, 46, 182-186.	0.4	40
147	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. <i>Oncotarget</i> , 2015, 6, 35087-35094.	0.8	40
148	Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. <i>SpringerPlus</i> , 2015, 4, 255.	1.2	40
149	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
150	Control of Chemotherapy-Induced Diarrhea with Octreotide. <i>Oncology</i> , 1994, 51, 70-73.	0.9	39
151	A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. <i>British Journal of Cancer</i> , 2001, 84, 470-474.	2.9	39
152	Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. <i>Annals of Oncology</i> , 2002, 13, 1882-1892.	0.6	39
153	Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. <i>British Journal of Cancer</i> , 2007, 97, 92-97.	2.9	39
154	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010, 29, 164.	3.5	39
155	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 630-637.	3.3	38
156	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0152079.	1.1	38
157	Tumor Markers in the Diagnosis of Malignant Serous Effusions. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 247-250.	0.6	38
158	GD2 expression in breast cancer. <i>Oncotarget</i> , 2017, 8, 31592-31600.	0.8	38
159	Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?. <i>ESMO Open</i> , 2017, 2, e000206.	2.0	37
160	Novel therapeutic approaches to cancer patients with bone metastasis. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 40, 239-250.	2.0	36
161	Pain and its treatment in hospitalized patients with metastatic cancer. <i>Supportive Care in Cancer</i> , 2003, 11, 587-592.	1.0	36
162	Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. <i>Lung Cancer</i> , 2005, 49, 371-376.	0.9	36

#	ARTICLE	IF	CITATIONS
163	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. <i>Oncotarget</i> , 2017, 8, 23871-23879.	0.8	36
164	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e72843.	1.1	36
165	Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epirubicin, 5-fluorouracil, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 1998, 78, 390-393.	2.9	35
166	Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	35
167	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 309-324.	2.0	35
168	COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 526-530.	0.6	34
169	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan+cetuximab. <i>Annals of Oncology</i> , 2012, 23, 1706-1712.	0.6	34
170	Different doses of pamidronate in patients with painful osteolytic bone metastases. <i>Supportive Care in Cancer</i> , 1998, 6, 139-143.	1.0	33
171	Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. <i>Lung Cancer</i> , 2006, 53, 103-109.	0.9	33
172	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2014, 9, e105268.	1.1	33
173	Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. <i>Supportive Care in Cancer</i> , 2015, 23, 621-626.	1.0	33
174	Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study. <i>Hepatology Research</i> , 2021, 51, 1229-1241.	1.8	33
175	BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival. <i>Anticancer Research</i> , 2017, 37, 7043-7048.	0.5	33
176	Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. <i>Journal of Biological Regulators and Homeostatic Agents</i> , 2014, 28, 555-63.	0.7	33
177	Recombinant Human Erythropoietin Treatment in Elderly Cancer Patients with Cisplatin-Associated Anemia. <i>Oncology</i> , 1995, 52, 422-426.	0.9	32
178	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 2000, 11, 1309-1312.	0.6	32
179	Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. <i>Lung Cancer</i> , 2003, 41, 101-106.	0.9	32
180	Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. <i>Annals of Oncology</i> , 2003, 14, ii25-ii29.	0.6	32

#	ARTICLE	IF	CITATIONS
181	Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. <i>BMC Cancer</i> , 2006, 6, 125.	1.1	32
182	Pancreatic cancer: Progress in cancer therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 67, 27-38.	2.0	32
183	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	1.9	32
184	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1547-1559.	2.0	32
185	Effects of Calcium and Vitamin Supplementation on Colon Cell Proliferation in Colorectal Cancer. <i>Cancer Investigation</i> , 2000, 18, 411-416.	0.6	31
186	Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors. <i>New England Journal of Medicine</i> , 2013, 368, 2042-2043.	13.9	31
187	Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy. <i>Gastroenterology Research and Practice</i> , 2014, 2014, 1-9.	0.7	31
188	Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. <i>European Journal of Internal Medicine</i> , 2019, 59, 27-33.	1.0	31
189	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. <i>Cancer Management and Research</i> , 2021, Volume 13, 9379-9389.	0.9	31
190	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. <i>Annals of Oncology</i> , 2015, 26, 2341-2346.	0.6	30
191	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , 2017, 7, 42499.	1.6	30
192	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	0.9	30
193	Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 816-817.	0.5	30
194	Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. <i>Oncotarget</i> , 2016, 7, 82648-82657.	0.8	30
195	eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , 2016, 7, 27988-27999.	0.8	30
196	Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. <i>European Journal of Cancer</i> , 1992, 28, 482-483.	1.3	29
197	Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 1997, 5, 314-317.	1.0	29
198	KIT and PDGFR $\beta$ mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. <i>Annals of Oncology</i> , 2008, 19, 706-710.	0.6	29

#	ARTICLE	IF	CITATIONS
199	Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 92, 208-217.	2.0	29
200	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771.	0.5	29
201	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , 2020, 15, e0232449.	1.1	29
202	Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. <i>British Journal of Cancer</i> , 1993, 67, 156-158.	2.9	28
203	A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. <i>European Journal of Cancer</i> , 1997, 33, 1699-1702.	1.3	28
204	Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. <i>Gastroenterology</i> , 1997, 113, 767-772.	0.6	28
205	Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 137-141.	0.9	28
206	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165.	2.0	28
207	Personalized Risk-Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. <i>Oncologist</i> , 2020, 25, e1013-e1020.	1.9	28
208	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. <i>Oncotarget</i> , 2015, 6, 32161-32168.	0.8	28
209	Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Annals of Oncology</i> , 2003, 14, 205-208.	0.6	27
210	Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009, 20, iv37-iv40.	0.6	27
211	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 272-283.	2.0	27
212	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 321-331.	2.7	27
213	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 155-162.	1.4	27
214	Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 651-655.	1.7	26
215	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. <i>Cancer</i> , 2013, 119, 3429-3435.	2.0	26
216	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 264-274.	2.0	26

#	ARTICLE	IF	CITATIONS
217	Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). <i>Tumori</i> , 2017, 103, 9-14.	0.6	26
218	The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. <i>Oncotarget</i> , 2017, 8, 9144-9154.	0.8	26
219	&lt;p&gt;Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2981-2988.	1.0	26
220	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , 2016, 7, 15243-15251.	0.8	26
221	High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A â€œGISCADâ€™ phase III study. <i>Annals of Oncology</i> , 1997, 8, 169-174.	0.6	25
222	High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. <i>Supportive Care in Cancer</i> , 2000, 8, 65-67.	1.0	25
223	Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. <i>Annals of Oncology</i> , 2006, 17, 1661-1664.	0.6	25
224	Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. <i>Journal of Translational Medicine</i> , 2012, 10, 71.	1.8	25
225	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016, 6, 25195.	1.6	25
226	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. <i>European Journal of Cancer</i> , 2017, 83, 106-115.	1.3	25
227	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 85.	1.8	25
228	Lenvatinib as a therapy for unresectable hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1069-1076.	1.1	25
229	Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.. <i>Oncoscience</i> , 2015, 2, 395-409.	0.9	25
230	Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?. <i>Oncotarget</i> , 2015, 6, 38737-38748.	0.8	25
231	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. <i>ESMO Open</i> , 2021, 6, 100330.	2.0	25
232	Chemotherapy for advanced pancreatic cancer: It may no longer be ignored. <i>Annals of Oncology</i> , 1999, 10, 105-110.	0.6	24
233	Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. <i>BMC Cancer</i> , 2001, 1, 9.	1.1	24
234	Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 25-32.	0.4	24

#	ARTICLE	IF	CITATIONS
235	New target therapies in advanced pancreatic cancer. <i>Annals of Oncology</i> , 2006, 17, v148-v152.	0.6	24
236	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. <i>Cancer Treatment Reviews</i> , 2009, 35, 451-462.	3.4	24
237	Clinical impact of different exosomesâ€™ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. <i>PLoS ONE</i> , 2019, 14, e0215990.	1.1	24
238	Role of SIRT-3, p-mTOR and HIF-1 $\alpha$ in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1503.	1.8	24
239	Locally advanced rectal cancer: The importance of a multidisciplinary approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 17279.	1.4	24
240	Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. <i>Anticancer Research</i> , 2013, 33, 2737-42.	0.5	24
241	Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. <i>Annals of Oncology</i> , 1999, 10, 217-222.	0.6	23
242	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 795-803.	1.7	23
243	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. <i>Radiation Oncology</i> , 2018, 13, 83.	1.2	23
244	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , 2019, 11, 1023.	1.7	23
245	Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) <i>TJ ETQq1 1 0.784314 rgBT4 Overlook</i>	1.1	23
246	Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?. <i>Annals of Oncology</i> , 1997, 8, 561-567.	0.6	22
247	The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase II Study. <i>Breast Cancer Research and Treatment</i> , 2003, 78, 29-36.	1.1	22
248	A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. <i>British Journal of Cancer</i> , 2003, 89, 1428-1432.	2.9	22
249	Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. <i>Advances in Urology</i> , 2012, 2012, 1-5.	0.6	22
250	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 563.	1.0	22
251	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 206-219.	2.0	22
252	Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). <i>Targeted Oncology</i> , 2016, 11, 489-500.	1.7	22

#	ARTICLE	IF	CITATIONS
253	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. <i>Scientific Reports</i> , 2016, 6, 24136.	1.6	22
254	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. <i>Scientific Reports</i> , 2017, 7, 45703.	1.6	22
255	Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. <i>Cancer Biology and Therapy</i> , 2018, 19, 879-886.	1.5	22
256	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , 2019, 6, 92-107.	0.3	22
257	Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. <i>European Journal of Cancer</i> , 2020, 127, 150-157.	1.3	22
258	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. <i>European Journal of Cancer</i> , 2019, 117, 84-90.	1.3	21
259	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. <i>Journal of Clinical Oncology</i> , 2008, 26, 4003-4003.	0.8	21
260	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. <i>Lung Cancer</i> , 2009, 64, 199-206.	0.9	20
261	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2012, 7, 104-110.	0.5	20
262	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2016, 17, 771-776.	1.0	20
263	The Clinical Impact of Teniposide in the Treatment of Elderly Patients with Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1997, 20, 477-478.	0.6	20
264	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 389.	0.8	20
265	5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: A pilot study. <i>Annals of Oncology</i> , 1993, 4, 83-84.	0.6	19
266	Nerve Growth Factor Receptor Immunoreactivity in Breast Cancer Patients. <i>Cancer Investigation</i> , 2001, 19, 692-697.	0.6	19
267	Cancer of pancreas. <i>Critical Reviews in Oncology/Hematology</i> , 2004, 50, 147-155.	2.0	19
268	Frequency of S492R Mutations in the Epidermal Growth Factor Receptor: Analysis of Plasma Dna from Metastatic Colorectal Cancer Patients Treated with Panitumumab or Cetuximab Monotherapy. <i>Annals of Oncology</i> , 2014, 25, ii109.	0.6	19
269	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 614-622.	3.4	19
270	Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. <i>Supportive Care in Cancer</i> , 2016, 24, 3139-45.	1.0	19



#	ARTICLE	IF	CITATIONS
271	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. <i>British Journal of Cancer</i> , 2017, 117, 315-321.	2.9	19
272	Is there a role for chemotherapy after local relapse in high-grade osteosarcoma?. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27792.	0.8	19
273	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. <i>ESMO Open</i> , 2021, 6, 100032.	2.0	19
274	Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination. <i>Annals of Oncology</i> , 2000, 11, 1053-1056.	0.6	18
275	Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy. <i>Annals of Oncology</i> , 2001, 12, 1091-1095.	0.6	18
276	Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. <i>Journal of Clinical Ultrasound</i> , 2001, 29, 354-358.	0.4	18
277	A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 673-678.	1.1	18
278	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. <i>Annals of Oncology</i> , 2009, 20, 1062-1067.	0.6	18
279	Prognostic Value for Incidental Antihypertensive Therapy With $\beta$ -Blockers in Metastatic Colorectal Cancer. <i>Medicine (United States)</i> , 2015, 94, e719.	0.4	18
280	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. <i>European Urology</i> , 2016, 69, 186-190.	0.9	18
281	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. <i>Clinical Colorectal Cancer</i> , 2017, 16, 38-43.	1.0	18
282	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	1.4	18
283	Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History. <i>Clinical Breast Cancer</i> , 2018, 18, e15-e24.	1.1	18
284	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. <i>Targeted Oncology</i> , 2021, 16, 249-254.	1.7	18
285	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. <i>Liver International</i> , 2021, 41, 2997-3008.	1.9	18
286	Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. <i>Oncotarget</i> , 2015, 6, 19305-19315.	0.8	18
287	Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 38, 93-104.	2.0	17
288	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. <i>Tumori</i> , 2006, 92, 384-388.	0.6	17

#	ARTICLE	IF	CITATIONS
289	Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?. <i>Lung Cancer</i> , 2010, 68, 433-437.	0.9	17
290	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2013, 113, 397-401.	1.4	17
291	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. <i>Pharmacogenomics</i> , 2013, 14, 1991-1998.	0.6	17
292	Cetuximab: still an option in the treatment of pancreatic cancer?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 791-801.	1.4	17
293	Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2015, 78, 1-6.	1.1	17
294	Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study. <i>Supportive Care in Cancer</i> , 2016, 24, 2225-2233.	1.0	17
295	<p>Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 9563-9569.	0.9	17
296	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103674.	2.0	17
297	Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. <i>Annals of Oncology</i> , 1992, 3, 489-491.	0.6	16
298	S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma. <i>Cancer</i> , 1998, 83, 1081-1085.	2.0	16
299	The Role of Levamisole in the Adjuvant Treatment of Stage III Colon Cancer Patients: A Randomized Trial of 5-Fluorouracil and Levamisole Versus 5-Fluorouracil Alone. <i>Cancer Investigation</i> , 2003, 21, 701-707.	0.6	16
300	The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 934-941.	3.4	16
301	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 303-309.	0.8	16
302	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. <i>Future Oncology</i> , 2015, 11, 107-119.	1.1	16
303	Breast ultrasonography (BU) in the screening protocol for women at hereditary/familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?. <i>International Journal of Cancer</i> , 2019, 144, 1001-1009.	2.3	16
304	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. <i>Cancers</i> , 2020, 12, 1022.	1.7	16
305	Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. <i>Cancers</i> , 2021, 13, 4938.	1.7	16
306	Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy. <i>Tumor Biology</i> , 2004, 25, 106-110.	0.8	15

#	ARTICLE	IF	CITATIONS
307	Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. <i>British Journal of Cancer</i> , 2005, 92, 1051-1054.	2.9	15
308	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 37-43.	1.1	15
309	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. <i>PLoS ONE</i> , 2012, 7, e38192.	1.1	15
310	Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. <i>Cancer Treatment Reviews</i> , 2014, 40, 495-506.	3.4	15
311	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 109-117.	0.6	15
312	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 113.e1-113.e7.	0.8	15
313	Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey. <i>Journal of Cancer</i> , 2016, 7, 1968-1978.	1.2	15
314	Borderline resectable pancreatic cancer: More than an anatomical concept. <i>Digestive and Liver Disease</i> , 2017, 49, 223-226.	0.4	15
315	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. <i>Targeted Oncology</i> , 2020, 15, 115-126.	1.7	15
316	Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4076-4076.	0.8	15
317	Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study. <i>Oncology</i> , 2006, 71, 374-381.	0.9	14
318	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. <i>PLoS ONE</i> , 2013, 8, e78544.	1.1	14
319	The route to personalized medicine in bladder cancer: where do we stand?. <i>Targeted Oncology</i> , 2015, 10, 325-336.	1.7	14
320	Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. <i>Supportive Care in Cancer</i> , 2015, 23, 1295-1302.	1.0	14
321	The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors. <i>Expert Review of Molecular Diagnostics</i> , 2015, 15, 979-987.	1.5	14
322	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479.	0.6	14
323	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. <i>Cancer Biology and Therapy</i> , 2020, 21, 891-898.	1.5	14
324	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. <i>Hpb</i> , 2021, 23, 915-920.	0.1	14

#	ARTICLE	IF	CITATIONS
325	Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 37599-37607.	0.8	14
326	Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen. <i>British Journal of Cancer</i> , 2002, 86, 213-217.	2.9	13
327	Treatment of Metastatic Colorectal Cancer With Monoclonal Antibody to Vascular Endothelial Growth Factor: Does the Metastatic Site Make the Difference?. <i>Journal of Clinical Oncology</i> , 2003, 21, 3542-3543.	0.8	13
328	Early Detection of Recurrences in the Follow-up of Primary Breast Cancer in an Asymptomatic or Symptomatic Phase. <i>Tumori</i> , 2004, 90, 276-279.	0.6	13
329	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. <i>Tumori</i> , 2005, 91, 505-512.	0.6	13
330	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. <i>Current Oncology Reports</i> , 2010, 12, 175-185.	1.8	13
331	Role of evaluating tumor-infiltrating lymphocytes, programmed death-1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. <i>International Journal of Oncology</i> , 2019, 55, 1157-1164.	1.4	13
332	Association of <i>NOS3</i> and <i>ANGPT2</i> Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , 2020, 26, 4485-4493.	3.2	13
333	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. <i>Medicine (United States)</i> , 2020, 99, e19958.	0.4	13
334	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1 $\alpha$ Final results of the ALICE-2 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-280.	0.8	13
335	The presence of bone (BM) and concomitant non-bone metastases (cNBM) significantly worsens the 2-year overall survival (OS) in breast cancer (BC) patients (PTS): Update of results in the moon study. <i>Journal of Clinical Oncology</i> , 2005, 23, 774-774.	0.8	13
336	Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. <i>Supportive Care in Cancer</i> , 1996, 4, 31-33.	1.0	12
337	Locoregional treatments of unresectable liver metastases from colorectal cancer. <i>Cancer Treatment Reviews</i> , 1998, 24, 3-14.	3.4	12
338	Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?. <i>Digestive and Liver Disease</i> , 2003, 35, 421-427.	0.4	12
339	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2245-2258.	0.9	12
340	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. <i>Current Urology Reports</i> , 2015, 16, 3.	1.0	12
341	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. <i>European Journal of Cancer</i> , 2019, 111, 1-7.	1.3	12
342	Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. <i>Cancers</i> , 2019, 11, 193.	1.7	12

#	ARTICLE	IF	CITATIONS
343	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785.	1.7	12
344	Regorafenib versus cabozantinib as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3665-3671.	1.2	12
345	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. <i>ESMO Open</i> , 2021, 6, 100190.	2.0	12
346	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. <i>ESMO Open</i> , 2021, 6, 100238.	2.0	12
347	Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II). <i>TJ ETQq1 1 0.784314 rgBT /Overlock 10</i>	1.0	11
348	Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 135.	0.8	12
349	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. <i>Anticancer Research</i> , 2013, 33, 5017-22.	0.5	12
350	Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. <i>British Journal of Cancer</i> , 1994, 69, 392-393.	2.9	11
351	Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 69, 223-236.	2.0	11
352	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. <i>Core Evidence</i> , 2010, 5, 61.	4.7	11
353	<i>KRAS</i> mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. <i>Future Oncology</i> , 2015, 11, 1905-1917.	1.1	11
354	Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. <i>BMC Research Notes</i> , 2016, 9, 497.	0.6	11
355	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 99-106.	2.0	11
356	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499.	1.3	11
357	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of) <i>TJ ETQq1 1 0.784314 rgBT /Overlock 10</i>	1.1	11
358	Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. <i>American Journal of Case Reports</i> , 2017, 18, 208-211.	0.3	11
359	Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma: A Focus on Oncological Outcomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 2828.	1.0	11
360	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 33381-33390.	0.8	11

#	ARTICLE	IF	CITATIONS
361	Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: A pooled analysis.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2060-2060.	0.8	11
362	Vascular Endothelial Growth Factor and p53 Expressions in Liver and Abdominal Metastases from Colon Cancer. <i>Tumor Biology</i> , 2003, 24, 77-81.	0.8	10
363	Social Support Networks and Depression of Women Suffering from Early-Stage Breast Cancer: A Case Control Study. <i>Journal of Psychosocial Oncology</i> , 2009, 27, 216-229.	0.6	10
364	Nuclear factor- $\kappa$ B predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. <i>Digestive and Liver Disease</i> , 2012, 44, 617-622.	0.4	10
365	Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. <i>Oncology Letters</i> , 2012, 4, 799-801.	0.8	10
366	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 323-327.	2.0	10
367	Resected biliary tract cancers: A novel clinical "pathological score correlates with global outcome. <i>Digestive and Liver Disease</i> , 2013, 45, 70-74.	0.4	10
368	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. <i>SpringerPlus</i> , 2015, 4, 743.	1.2	10
369	<i>Lgr5</i> expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. <i>Future Oncology</i> , 2015, 11, 1037-1045.	1.1	10
370	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
371	Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 244-249.	0.9	10
372	First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. <i>Clinical Breast Cancer</i> , 2019, 19, e701-e716.	1.1	10
373	Are we ready to describe response or progression to immunotherapy in lung cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 112-119.	2.0	10
374	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1479-1482.	0.5	10
375	Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 937-943.	1.5	10
376	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 554-560.	3.3	10
377	Nab-paclitaxel (Nab-P) and gemcitabine (G) as first-line chemotherapy (CT) in advanced pancreatic cancer (APDAC) elderly patients (pts): A "real-life" study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 424-424.	0.8	10
378	Gastric cancer treatment: a systematic review. <i>Oncology Reports</i> , 0, , .	1.2	10

#	ARTICLE	IF	CITATIONS
379	Drug therapy in diarrheal diseases in oncology/hematology patients. <i>Critical Reviews in Oncology/Hematology</i> , 1995, 18, 37-50.	2.0	9
380	S-phase fraction and tumor aneuploidy in colorectal carcinoma of young patients. , 1996, 78, 1857-1860.		9
381	A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. <i>British Journal of Cancer</i> , 1996, 74, 971-974.	2.9	9
382	Gastrointestinal Cancer Refractory to Chemotherapy: A Role for Octreotide?. <i>Chemotherapy</i> , 2001, 47, 127-133.	0.8	9
383	Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. <i>Annals of Oncology</i> , 2011, 22, 897-902.	0.6	9
384	HER family Receptor Expression and Prognosis in Pancreatic Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 327-332.	0.7	9
385	Altering macrophage polarization in the tumor environment: the role of response gene to complement 32. <i>Cellular and Molecular Immunology</i> , 2015, 12, 783-784.	4.8	9
386	Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma. <i>Tumori</i> , 2016, 102, 190-195.	0.6	9
387	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 426-431.	0.9	9
388	Emerging antibodies for the treatment of pancreatic cancer. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 39-51.	1.0	9
389	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 435-446.	0.7	9
390	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	9
391	Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102836.	2.0	9
392	Lenvatinib and pembrolizumab in advanced gastric cancer. <i>Lancet Oncology</i> , The, 2020, 21, 1004-1005.	5.1	9
393	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. <i>Cancer Treatment Reviews</i> , 2020, 86, 102020.	3.4	9
394	Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2010, 28, e13017-e13017.	0.8	9
395	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 740-740.	0.8	9
396	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. <i>PLoS ONE</i> , 2015, 10, e0120427.	1.1	9

#	ARTICLE	IF	CITATIONS
397	Emerging Immunotargets in Bladder Cancer. <i>Current Drug Targets</i> , 2016, 17, 757-770.	1.0	9
398	Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response. <i>Molecular and Clinical Oncology</i> , 2020, 12, 3-8.	0.4	9
399	Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 247-257.	1.1	8
400	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 332-341.	2.0	8
401	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial. <i>European Journal of Cancer</i> , 2021, 148, 422-429.	1.3	8
402	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. <i>Frontiers in Oncology</i> , 2021, 11, 637823.	1.3	8
403	Selecting the Best Treatment for an Individual Patient. <i>Recent Results in Cancer Research</i> , 2012, 196, 307-318.	1.8	8
404	Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials.. <i>Journal of Clinical Oncology</i> , 2011, 29, 2595-2595.	0.8	8
405	Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?. <i>Current Cancer Drug Targets</i> , 2013, 13, 313-325.	0.8	8
406	Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon- $\beta$ and folinic acid. The –GISCAD– experience. <i>European Journal of Cancer</i> , 1994, 30, 1611-1616.	1.3	7
407	Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 72-74.	1.1	7
408	Intensive Weekly Chemotherapy for Elderly Gastric Cancer Patients, Using 5-Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin and Glutathione with the Support of G-CSF. <i>Tumori</i> , 1995, 81, 32-35.	0.6	7
409	Chemo-embolization in the treatment of liver metastases from colorectal cancer. <i>Cancer Treatment Reviews</i> , 1996, 22, 355-363.	3.4	7
410	Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>British Journal of Cancer</i> , 1999, 79, 491-494.	2.9	7
411	Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors.. <i>Oncology Reports</i> , 2000, 7, 987-90.	1.2	7
412	The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. <i>Digestive and Liver Disease</i> , 2011, 43, 194-198.	0.4	7
413	Temperament and Character Traits Associated with Health-Related Quality of Life in Cancer Patients. <i>Tumori</i> , 2012, 98, 377-384.	0.6	7
414	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 143-150.	0.9	7



#	ARTICLE	IF	CITATIONS
415	Patient and Caregiver Needs in Oncology. An Italian Survey. <i>Tumori</i> , 2015, 101, 621-625.	0.6	7
416	Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. <i>Breast Journal</i> , 2017, 23, 610-611.	0.4	7
417	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). <i>Clinical Colorectal Cancer</i> , 2017, 16, 410-415.e1.	1.0	7
418	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. <i>Scientific Reports</i> , 2019, 9, 3668.	1.6	7
419	The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358.	0.6	7
420	High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. <i>Oncology Reports</i> , 2019, 42, 2750-2758.	1.2	7
421	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020, 35, 1513-1527.	1.0	7
422	From CENTRAL to SENTRAL (SErum aNGiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. <i>Cancers</i> , 2020, 12, 1330.	1.7	7
423	The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation. <i>Cancers</i> , 2021, 13, 671.	1.7	7
424	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. <i>Current Drug Targets</i> , 2014, 15, 1225-1230.	1.0	7
425	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofactory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 507-507.	0.8	7
426	Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. <i>Lung Cancer</i> , 2002, 35, 243-247.	0.9	6
427	Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy. <i>Tumori</i> , 2005, 91, 472-476.	0.6	6
428	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 2467-2478.	0.9	6
429	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. <i>Journal of Translational Medicine</i> , 2015, 13, 140.	1.8	6
430	Panitumumab for the treatment of metastatic colorectal cancer: a review. <i>Immunotherapy</i> , 2015, 7, 721-738.	1.0	6
431	Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. <i>Gastrointestinal Tumors</i> , 2018, 5, 14-20.	0.3	6
432	Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. <i>Breast Cancer</i> , 2019, 26, 520-523.	1.3	6

#	ARTICLE	IF	CITATIONS
433	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 82-90.e9.	1.0	6
434	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989028.	1.4	6
435	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. <i>Journal of Gastrointestinal Cancer</i> , 2022, 53, 289-298.	0.6	6
436	Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. <i>Journal of Clinical Oncology</i> , 2006, 24, 4031-4031.	0.8	6
437	Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4066-4066.	0.8	6
438	Chemotherapy for Advanced Pancreatic Cancer: The History is Changing. <i>Tumori</i> , 1998, 84, 308-311.	0.6	5
439	A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. <i>Annals of Oncology</i> , 1999, 10, 985-987.	0.6	5
440	Survival and quality of life in gastrointestinal tumors: Two different end points?. <i>Annals of Oncology</i> , 2001, 12, S31-S36.	0.6	5
441	Effective prevention of 5-fluorouracil-induced superficial phlebitis by ketoprofen lysine salt gel. <i>American Journal of Medicine</i> , 2003, 115, 415-417.	0.6	5
442	Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review. <i>Cancer Treatment Reviews</i> , 2006, 32, 333-347.	3.4	5
443	Molecular Biology for Stage II Colorectal Cancer: The Jury Is Still Out. <i>Journal of Clinical Oncology</i> , 2007, 25, 2861-2861.	0.8	5
444	Oral treatment for gastric cancer: new choices, better choices?. <i>Lancet Oncology</i> , The, 2008, 9, 188-189.	5.1	5
445	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 559-566.	1.1	5
446	Role of $\alpha$ 24 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. <i>Future Oncology</i> , 2013, 9, 1207-1214.	1.1	5
447	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. <i>OncoTargets and Therapy</i> , 2015, 8, 1149.	1.0	5
448	To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 154-160.	2.0	5
449	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. <i>Tumori</i> , 2021, 107, 550-555.	0.6	5
450	New findings on thymic epithelial tumors: Something is changing. <i>World Journal of Clinical Oncology</i> , 2015, 6, 96.	0.9	5

#	ARTICLE	IF	CITATIONS
451	Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. <i>Oncology Reports</i> , 0, , .	1.2	5
452	Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. <i>Journal of Clinical Oncology</i> , 2009, 27, 4017-4017.	0.8	5
453	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF. <i>Tumori</i> , 1995, 81, 32-5.	0.6	5
454	Compliance with breast and cervical cancer screening programs in women: results from a population-based study. <i>Tumori</i> , 2013, 99, 565-71.	0.6	5
455	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4069-4069.	0.8	5
456	Breast cancer developing after therapy for Hodgkin's disease. <i>Clinical Oncology</i> , 1993, 5, 61-62.	0.6	4
457	Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 38, 385-386.	1.1	4
458	Liver metastases from colorectal cancer. <i>Annals of Oncology</i> , 1997, 8, 393-399.	0.6	4
459	Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients. <i>International Journal of Biological Markers</i> , 2002, 17, 63-66.	0.7	4
460	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. <i>Oncology</i> , 2005, 68, 212-216.	0.9	4
461	Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. <i>Expert Opinion on Therapeutic Targets</i> , 2006, 10, 281-287.	1.5	4
462	Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinical Pathologic Score Correlates With Global Outcome. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 1437-1443.	0.4	4
463	A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. <i>Annals of Oncology</i> , 2012, 23, 1081-1082.	0.6	4
464	A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Afibercept in Cancer Patients Treated With Docetaxel. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 495-504.	0.8	4
465	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. <i>Pharmacogenomics</i> , 2014, 15, 1701-1715.	0.6	4
466	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1185-1198.	1.9	4
467	Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. <i>Oncology Reports</i> , 2016, 36, 755-762.	1.2	4
468	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , 2019, 6, 71-80.	0.3	4

#	ARTICLE	IF	CITATIONS
469	Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 821-828.	1.2	4
470	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. <i>Cancers</i> , 2020, 12, 1153.	1.7	4
471	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	1.9	4
472	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. <i>Hepatology Research</i> , 2021, 51, 796-802.	1.8	4
473	Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. <i>Hpb</i> , 2022, 24, 244-254.	0.1	4
474	Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment.. <i>Journal of Clinical Oncology</i> , 2015, 33, 412-412.	0.8	4
475	Temperament and character traits associated with health-related quality of life in cancer patients. <i>Tumori</i> , 2012, 98, 377-84.	0.6	4
476	Occult breast cancer: the uncommon presentation of a common disease. <i>Chinese Clinical Oncology</i> , 2019, 8, S10-S10.	0.4	4
477	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. <i>Journal of Clinical Oncology</i> , 2016, 34, 519-519.	0.8	4
478	Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer. <i>Anti-Cancer Drugs</i> , 1996, 7, 43-47.	0.7	3
479	A phase I trial of 5-fluorouracil, leucovorin and interferon- $\gamma$ administered by 24 h infusion in metastatic colorectal carcinoma. <i>Anti-Cancer Drugs</i> , 1996, 7, 520-524.	0.7	3
480	Gemcitabine (GEM) and 5-fluorouracil (5 FU) in advanced pancreatic cancer: A GISCAD phase II study. <i>European Journal of Cancer</i> , 1997, 33, S280.	1.3	3
481	A Pilot Clinical Trial of Postoperative Intensive Weekly Chemotherapy Using Cisplatin, Epi-Doxorubicin, 5-Fluorouracil, 6S-Leucovorin, Glutathione and Filgrastim in Patients with Resected Gastric Cancer. <i>Tumori</i> , 1998, 84, 368-371.	0.6	3
482	An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 1999, 35, S375-S376.	1.3	3
483	SPECIAL DEPARTMENTS. <i>Journal of Clinical Oncology</i> , 2000, 18, 445-445.	0.8	3
484	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. <i>Digestive and Liver Disease</i> , 2012, 44, 74-79.	0.4	3
485	2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in <i>Journal of Cancer</i> , 2015, 51, S329.	1.3	3
486	Gender differences and outcome of melanoma patients. <i>Journal of Translational Medicine</i> , 2015, 13, P13.	1.8	3

#	ARTICLE	IF	CITATIONS
487	Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients. <i>Annals of Oncology</i> , 2017, 28, vi5.	0.6	3
488	The DISTINCTIVE study: A biologically enriched phase II study of second-line folfiri/aflibercept in prospectively stratified, anti-EGFR resistant, metastatic colorectal cancer patients with RAS Validated wild type status - Trial in progress. <i>Annals of Oncology</i> , 2018, 29, v82.	0.6	3
489	Dabrafenib+trametinib combination in real-world practice: an Italian experience. <i>Future Oncology</i> , 2018, 14, 2045-2052.	1.1	3
490	Anti-EGFR therapy in oesophagogastric cancer: precise but not enough. <i>Annals of Oncology</i> , 2018, 29, 1884-1885.	0.6	3
491	Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM). <i>Journal of Clinical Nursing</i> , 2020, 29, 119-129.	1.4	3
492	Maspin Staining and Its Use as Biomarker in Lung Cancer. <i>Biomarkers in Disease</i> , 2015, , 345-358.	0.0	3
493	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. <i>PLoS ONE</i> , 2016, 11, e0159146.	1.1	3
494	CARBOPLATIN ASSOCIATED ANEMIA TREATED WITH SUBCUTANEOUS ERYTHROPOIETIN - A PILOT-STUDY. <i>Oncology Reports</i> , 0, , .	1.2	3
495	Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4025-4025.	0.8	3
496	Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 448-448.	0.8	3
497	INTENSIVE WEEKLY CHEMOTHERAPY FOR ADVANCED GASTRIC-CANCER USING 5-FLUOROURACIL, CISPLATIN, EPI-DOXORUBICIN, 6S-LEUCOVORIN AND GRANULOCYTE-COLONY-STIMULATING FACTOR. <i>International Journal of Oncology</i> , 1993, 3, 535-8.	1.4	2
498	Have enteric infections a role in 5-fluorouracil-associated diarrhea?. <i>Supportive Care in Cancer</i> , 1995, 3, 322-323.	1.0	2
499	Recombinant human erythropoietin in chemotherapy-associated anemia. <i>Cancer Treatment Reviews</i> , 1995, 21, 553-564.	3.4	2
500	A cost-benefit analysis of chemotherapy for gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2109-2114.	0.9	2
501	Hepatic Artery Administration of Docetaxel in Liver Metastases from Breast Carcinoma: A Feasibility Study. <i>Tumori</i> , 2005, 91, 121-125.	0.6	2
502	Paclitaxel and Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil for Patients With Stage IIIC Breast Cancer With Ten or More Involved Axillary Lymph Nodes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 380-384.	0.6	2
503	Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. <i>Familial Cancer</i> , 2012, 11, 675-680.	0.9	2
504	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. <i>Cellular and Molecular Immunology</i> , 2015, 12, 122-124.	4.8	2

#	ARTICLE	IF	CITATIONS
505	Maintenance therapy for metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2015, 16, 1281-1282.	5.1	2
506	Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, vi13-vi14.	0.6	2
507	Somatostatin analogs: is one better than other?. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 817-819.	1.4	2
508	Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. <i>Annals of Oncology</i> , 2018, 29, viii316.	0.6	2
509	Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease. <i>Journal of Thoracic Oncology</i> , 2018, 13, e152-e153.	0.5	2
510	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. <i>Medical Oncology</i> , 2021, 38, 17.	1.2	2
511	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). <i>Cancers</i> , 2021, 13, 1304.	1.7	2
512	Over D1 lymph-nodes dissection may question the value of post-operative radiotherapy as a part of an adjuvant program in radically resected gastric cancer patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 4041-4041.	0.8	2
513	Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). <i>Journal of Clinical Oncology</i> , 2004, 22, 4237-4237.	0.8	2
514	Chemotherapy use at the end of life: An analysis of the decision making process. <i>Journal of Clinical Oncology</i> , 2004, 22, 6081-6081.	0.8	2
515	Ca 19.9 as an early predictor of response to first- and second-line treatment in patients with pancreatic cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 15547-15547.	0.8	2
516	The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab.. <i>Journal of Clinical Oncology</i> , 2011, 29, 404-404.	0.8	2
517	Different effects of sunitinib, sorafenib, and pazopanib on inducing cancer cell death: The role of autophagy.. <i>Journal of Clinical Oncology</i> , 2013, 31, 270-270.	0.8	2
518	LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. <i>Journal of Clinical Oncology</i> , 2014, 32, 497-497.	0.8	2
519	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14623-e14623.	0.8	2
520	Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients. <i>International Journal of Biological Markers</i> , 2002, 17, 63-66.	0.7	2
521	Gastric cancer: toward a cisplatin-free disease?. <i>Journal of Gastrointestinal Oncology</i> , 2014, 5, 318-22.	0.6	2
522	Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. , 2009, 31, 417-23.		2

#	ARTICLE	IF	CITATIONS
523	Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. <i>Anti-Cancer Drugs</i> , 1995, 6, 608-611.	0.7	1
524	Angiosuppression and Chemotherapy: Strategies Aimed at Their Integration in Cancer Patients. <i>International Journal of Biological Markers</i> , 1999, 14, 239-242.	0.7	1
525	La Gestione Del Paziente Con Carcinoma Gastrico. <i>Tumori</i> , 2002, 1, S3-S10.	0.6	1
526	P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 535-542.	0.6	1
527	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epi-doxorubicin in a Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1346-1347.	3.0	1
528	Chemotherapy-Free Intervals in Patients With Metastatic Colorectal Cancer: A Tale of Two Cities?. <i>Journal of Clinical Oncology</i> , 2010, 28, e268-e269.	0.8	1
529	PP 22 Analysis of HER-3, insulin-growth factor-1 (IGF-1), nuclear factor $\kappa$ -B (NF- $\kappa$ B) and epidermal growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecan+cetuximab. <i>European Journal of Cancer</i> , 2011, 47, S29.	1.3	1
530	Professional failure: how do oncologists feel it?. <i>Annals of Oncology</i> , 2011, 22, 2696-2697.	0.6	1
531	Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study. <i>Annals of Oncology</i> , 2012, 23, ix205-ix206.	0.6	1
532	Clinical Impact of [11C]-Methionine Positron Emission Tomography on the Treatment of Primary and Recurrent Gliomas. <i>Annals of Oncology</i> , 2012, 23, ix148.	0.6	1
533	3092 Systemic immune-inflammation index (SII) in patients with advanced non-small cell lung cancer (nscl). <i>European Journal of Cancer</i> , 2015, 51, S630.	1.3	1
534	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: preliminary results. <i>Annals of Oncology</i> , 2015, 26, vi104.	0.6	1
535	Endocrine therapy is not effective in BRCA2 mutated breast cancers even when they express hormonal receptors. <i>Annals of Oncology</i> , 2015, 26, vi11.	0.6	1
536	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) $\geq$ 4 months (m). <i>Annals of Oncology</i> , 2016, 27, iv47.	0.6	1
537	BRCA mutations and IGF-R1 expression in modulating sensitivity to Trastuzumab in patients with HER2-positive breast cancer. <i>Annals of Oncology</i> , 2016, 27, iv65.	0.6	1
538	Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. <i>Annals of Oncology</i> , 2016, 27, iv69.	0.6	1
539	ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study. <i>Digestive and Liver Disease</i> , 2016, 48, e23.	0.4	1
540	Anal cancer: from an orphan disease to a curable malignancy?. <i>Lancet Oncology</i> , The, 2017, 18, 415-416.	5.1	1

#	ARTICLE	IF	CITATIONS
541	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. <i>Digestive and Liver Disease</i> , 2017, 49, e19.	0.4	1
542	Trifluridine tipiracil (TAS 102) in patients with stage IV pretreated colorectal neoplasm: an experience from Rimini City Hospital. <i>Annals of Oncology</i> , 2017, 28, iii117-iii118.	0.6	1
543	Is there an optimal choice in refractory colorectal cancer? A network meta-analysis. <i>Annals of Oncology</i> , 2019, 30, iv14.	0.6	1
544	Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs). <i>Annals of Oncology</i> , 2019, 30, iv75.	0.6	1
545	Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time?. <i>Gastroenterology</i> , 2021, 160, 1423-1424.	0.6	1
546	High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen. <i>Journal of Clinical Oncology</i> , 2005, 23, 4023-4023.	0.8	1
547	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: A randomised phase II trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 13521-13521.	0.8	1
548	Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results. <i>Journal of Clinical Oncology</i> , 2008, 26, 2032-2032.	0.8	1
549	A phase III multicenter trial comparing two different sequences of second/third line therapy		



#	ARTICLE	IF	CITATIONS
559	KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, e15207-e15207.	0.8	1
560	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. Journal of Clinical Oncology, 2016, 34, 547-547.	0.8	1
561	Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach?. World Journal of Clinical Oncology, 2016, 7, 131.	0.9	1
562	Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.. Journal of Clinical Oncology, 2016, 34, 632-632.	0.8	1
563	Angiogenetic pathway as a therapeutic target in renal cell carcinoma. , 2012, 34, 15-22.		1
564	Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Tumori, 2011, 97, 275-9.	0.6	1
565	p53 Status as potential predictor for response to chemotherapy in locally advanced gastric cancer. European Journal of Cancer, 1997, 33, S276.	1.3	0
566	Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5fu. European Journal of Cancer, 1999, 35, S80.	1.3	0
567	DCC and p53 protein expression in early stages of gastric cancer. European Journal of Cancer, 1999, 35, S192.	1.3	0
568	Pre-operative treatment modalities in gastric cancer patients. Annals of Oncology, 2005, 16, iv106-iv109.	0.6	0
569	“Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review” [Cancer Treatment Reviews 32(5) (2006) 333-347]. Cancer Treatment Reviews, 2007, 33, 497.	3.4	0
570	[354] THE SELECTIVE INHIBITION OF THE NA+/H+ EXCHANGER BY CARIPORIDE INCREASES THE ANTINEOPLASTIC EFFECT OF GEMCITABINE IN HUMAN CHOLANGIOCARCINOMA CELLS THROUGH MODULATION OF PHARMACORESISTANCE. Journal of Hepatology, 2007, 46, S138.	1.8	0
571	Hepatocellular carcinoma: The beginning of a long journey. Digestive and Liver Disease, 2009, 41, 707-708.	0.4	0
572	8743 POSTER Efficacy of Fotemustine in Recurrent Malignant Glioma According to Time to Adjuvant Temozolomide Failure “ a Pooled Analysis. European Journal of Cancer, 2011, 47, S586.	1.3	0
573	6612 POSTER The Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-receptors Genotyping in Guiding the Metastatic Process in Radically Resected Gastric Cancer Patients. European Journal of Cancer, 2011, 47, S475.	1.3	0
574	1005 ORAL HER-3, IGF-1, NF K-B and EGFR Gene Copy Number in the Prediction of Clinical Outcome for Colorectal Cancer Patients Receiving Irinotecan-cetuximab. European Journal of Cancer, 2011, 47, S98.	1.3	0
575	PP 23 The role of vascular endothelial growth factor (VEGF) and VEGF-receptors genotyping in guiding the metastatic process in radically resected gastric cancer patients. European Journal of Cancer, 2011, 47, S30.	1.3	0
576	1035 THE ROLE OF VEGF AND VEGFR POLYMORPHISMS IN THE PREDICTION OF CLINICAL OUTCOME FOR ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB. Journal of Hepatology, 2012, 56, S405.	1.8	0

#	ARTICLE	IF	CITATIONS
577	Beta 4 Integrin Polymorphism Mediate an Alternative Resistance Pathway in HER-3 Negative, K-RAS Wild Type Metastatic Colorectal Patients Receiving Irinotecan Cetuximab. <i>Annals of Oncology</i> , 2012, 23, ix86.	0.6	0
578	Potential Clinical Application and Trials. <i>Annals of Oncology</i> , 2012, 23, ix37.	0.6	0
579	Clinical Outcome of advanced Gastric Cancer (GC) Patients Receiving First-Line Chemotherapy According to Tumour Histology and Location. <i>Annals of Oncology</i> , 2012, 23, ix250.	0.6	0
580	The Role of Hedgehog (HH) Signaling in the Prediction of Clinical Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC). <i>Annals of Oncology</i> , 2012, 23, ix533.	0.6	0
581	Cancer Stem Cell Genetic Profile as Predictor of Relapse in Radically Resected Colorectal Cancer. <i>Annals of Oncology</i> , 2012, 23, ix86-ix87.	0.6	0
582	Primary Resistance to First-Line Bevacizumab in Metastatic Colorectal Cancer: Implications on Prognosis. <i>Annals of Oncology</i> , 2012, 23, ix219-ix220.	0.6	0
583	The Role of Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms in the Prediction of Clinical Outcome for advanced Hepatocellular Carcinoma Receiving Sorafenib. <i>Annals of Oncology</i> , 2012, 23, ix243.	0.6	0
584	Prognostic Factors in Early Stage Non-Small Cell Lung Cancer (NSCLC): The Importance of Number of Resected Lymph Nodes and Vascular Invasion. <i>Annals of Oncology</i> , 2012, 23, ix387.	0.6	0
585	Pancreatic Ductal Adenocarcinoma: A Homogeneous Morphologically but Molecularly Heterogeneous Tumor. IMPLICATIONS for its Management. <i>Annals of Oncology</i> , 2012, 23, ix239.	0.6	0
586	Prognostic Significance of EGFR, HER-2, CEA on Circulatingtumour Cells (CTCS) in Patients with Metastatic Non-Small-Cell Lung Cancer (MNSCLC). <i>Annals of Oncology</i> , 2012, 23, ix431.	0.6	0
587	Adjuvant chemotherapy in colon cancer: Can we improve quality of care?. <i>Digestive and Liver Disease</i> , 2013, 45, 637-638.	0.4	0
588	HER2I Resistance. <i>Annals of Oncology</i> , 2013, 24, ix17.	0.6	0
589	Baseline Neutrophil to Lymphocyte Ratio Correlates with Tumor Stage in Locally Advanced Breast Cancer Patients. <i>Annals of Oncology</i> , 2014, 25, iv113.	0.6	0
590	Neutrophil/Lymphocyte Ratio and Piastrinosis Correlate with Clinical Outcome in Metastatic Colorectal Cancer Patients Receiving Regorafenib. <i>Annals of Oncology</i> , 2014, 25, iv181.	0.6	0
591	Prognosis of Brca1 and Brca2-Related Breast Cancers: are There Differences?. <i>Annals of Oncology</i> , 2014, 25, iv254.	0.6	0
592	PR20 Biology of BRCA-related triple-negative breast cancer: which is the difference with the others?. <i>Breast</i> , 2014, 23, S8.	0.9	0
593	P80 ANGIOGENESIS POLYMORPHISMS PROFILE IN THE PREDICTION OF CLINICAL OUTCOME OF ADVANCED HCC PATIENTS RECEIVING SORAFENIB: COMBINED ANALYSIS OF VEGF AND HIF-1 $\alpha$ . THE ALICE-2 STUDY. <i>Journal of Hepatology</i> , 2014, 60, S93.	1.8	0
594	2110 Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). <i>European Journal of Cancer</i> , 2015, 51, S366.	1.3	0

#	ARTICLE	IF	CITATIONS
595	2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. <i>European Journal of Cancer</i> , 2015, 51, S380-S381.	1.3	0
596	2390 LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy. <i>European Journal of Cancer</i> , 2015, 51, S467.	1.3	0
597	2580 Multigene profiling in incidentally- and clinically detected prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, S504-S505.	1.3	0
598	Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study. <i>Annals of Oncology</i> , 2015, 26, vi37.	0.6	0
599	Secondary breast cancer prevention: it's time to get moving!. <i>Annals of Oncology</i> , 2015, 26, vi147.	0.6	0
600	Mismatch repair protein expression and Hedgehog signalling pathways in human pancreatic cancer. <i>Annals of Oncology</i> , 2015, 26, vi92.	0.6	0
601	P0313 : Correlation between VEGF and VEGF-R polymorphisms, toxicity and clinical outcome in HCC patients receiving sorafenib. <i>Journal of Hepatology</i> , 2015, 62, S426.	1.8	0
602	2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs). <i>European Journal of Cancer</i> , 2015, 51, S512-S513.	1.3	0
603	BRCA1/2 mutations and hereditary breast cancer: clinical phenotype, type of mutation and founder effect. <i>Annals of Oncology</i> , 2015, 26, vi15.	0.6	0
604	Soft tissue sarcoma after haematological malignancies in childhood/adolescence: a hospital series. <i>Annals of Oncology</i> , 2015, 26, vi30.	0.6	0
605	Role of different toxicity profile on outcome for colorectal cancer patients receiving Regorafenib monotherapy. <i>Annals of Oncology</i> , 2015, 26, vi51.	0.6	0
606	Clinical and pathological predictors of outcome for malignant pleural mesothelioma. <i>Annals of Oncology</i> , 2015, 26, vi89.	0.6	0
607	Risk for developing hyponatraemia in cancer patients treated with targeted therapies: a meta-analysis. <i>Annals of Oncology</i> , 2015, 26, vi135.	0.6	0
608	Evaluation of clinical and pathological features in patients with Lynch Syndrome-related Endometrial Cancer: a single centre experience. <i>Annals of Oncology</i> , 2015, 26, vi34.	0.6	0
609	Bone metastases (BMs) in patients with advanced non-small cell lung cancer (NSCLC): do they always correlate with poor prognosis?. <i>Annals of Oncology</i> , 2015, 26, vi86.	0.6	0
610	Impact and prognostic role of single-nucleotide polymorphisms (SNPs) in thymic lesions. <i>Annals of Oncology</i> , 2015, 26, vi79.	0.6	0
611	Advanced non-small cell lung cancer (NSCLC): the prognostic role of systemic Immune-Inflammation Index (SII). <i>Annals of Oncology</i> , 2015, 26, vi74.	0.6	0
612	There is a difference of vitamin D receptor gene (VDR) single-nucleotide polymorphisms (SNPs) frequencies between malignant melanoma patients and healthy volunteers and by sex?. <i>Annals of Oncology</i> , 2015, 26, vi26.	0.6	0

#	ARTICLE	IF	CITATIONS
613	eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. <i>Digestive and Liver Disease</i> , 2015, 47, e8.	0.4	0
614	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). <i>Annals of Oncology</i> , 2016, 27, vi145.	0.6	0
615	Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis. <i>Annals of Oncology</i> , 2016, 27, iv21.	0.6	0
616	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). <i>Annals of Oncology</i> , 2016, 27, iv22.	0.6	0
617	Mismatch repair protein expression and inflammation in human pancreatic cancer. <i>Annals of Oncology</i> , 2016, 27, iv23.	0.6	0
618	Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. <i>Annals of Oncology</i> , 2016, 27, iv73.	0.6	0
619	Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. <i>Annals of Oncology</i> , 2016, 27, iv75.	0.6	0
620	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC treated with sorafeinb: Results from a retrospective analysis of HCC-AVR group. <i>Digestive and Liver Disease</i> , 2016, 48, e36.	0.4	0
621	Reply to O. Corli et al and M. Lucchesi et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3580-3581.	0.8	0
622	Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GiSCAD) CENTRAL trial (ColorEctalvastiNTRiALdh). <i>Annals of Oncology</i> , 2016, 27, vi178.	0.6	0
623	Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study. <i>Annals of Oncology</i> , 2016, 27, vi239.	0.6	0
624	An Italian cost-effectiveness analysis of paclitaxel albumin (nab <sup>®</sup> -paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: The APICE study. <i>Annals of Oncology</i> , 2016, 27, vi358.	0.6	0
625	Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. <i>Annals of Oncology</i> , 2016, 27, iv44.	0.6	0
626	Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. <i>Annals of Oncology</i> , 2016, 27, vi84.	0.6	0
627	BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer. <i>Annals of Oncology</i> , 2016, 27, vi51.	0.6	0
628	Advanced gastric cancer: is there an optimal chemotherapy regimen?. <i>Expert Review of Quality of Life in Cancer Care</i> , 2017, 2, 123-132.	0.6	0
629	Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2017, 49, e42.	0.4	0
630	Quality of Life and Anxious-depressive Symptoms in Cancer Patients Undergoing Mindfulness-based Interventions: Feasibility and Preliminary Outcomes on Prospective Single-centre Case-control Study (MIND4ME St.). <i>European Psychiatry</i> , 2017, 41, S252-S252.	0.1	0

#	ARTICLE	IF	CITATIONS
631	Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. <i>Annals of Oncology</i> , 2017, 28, vi38-vi39.	0.6	0
632	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. <i>Annals of Oncology</i> , 2017, 28, vi9-vi10.	0.6	0
633	The prognostic impact of sidedness across all stages during the last 20 years: the "Modena Cancer Registry" experience. <i>Annals of Oncology</i> , 2017, 28, vi10.	0.6	0
634	Family history of pancreatic cancer in BRCA1/2 testing criteria. <i>Annals of Oncology</i> , 2017, 28, vi46.	0.6	0
635	Small bowel adenocarcinoma (SBA) is a rare and heterogeneous disease: results of a retrospective analysis. <i>Annals of Oncology</i> , 2017, 28, vi50-vi51.	0.6	0
636	The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer. <i>Annals of Oncology</i> , 2018, 29, viii196.	0.6	0
637	General and dedicated cancer emergency room: Clinical and financial implications. <i>Annals of Oncology</i> , 2018, 29, viii623.	0.6	0
638	ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC). <i>Annals of Oncology</i> , 2018, 29, vi30.	0.6	0
639	First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?. <i>Annals of Oncology</i> , 2018, 29, viii110.	0.6	0
640	A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht). <i>Annals of Oncology</i> , 2018, 29, viii263.	0.6	0
641	A novel electronic tool to implement palliative sedation (PS) in a department of oncologic medicine. <i>Annals of Oncology</i> , 2018, 29, viii554.	0.6	0
642	The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. <i>Annals of Oncology</i> , 2018, 29, viii264.	0.6	0
643	Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma. <i>Annals of Oncology</i> , 2018, 29, viii641-viii642.	0.6	0
644	P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. <i>Annals of Oncology</i> , 2018, 29, v58-v59.	0.6	0
645	Characterization of mismatch repair deficiency in biliary tract cancer. <i>Annals of Oncology</i> , 2019, 30, iv76.	0.6	0
646	A new prognostic score for biliary tract cancer: a multicenter experience. <i>Annals of Oncology</i> , 2019, 30, iv92.	0.6	0
647	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. <i>Annals of Oncology</i> , 2019, 30, iv113.	0.6	0
648	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. <i>Annals of Oncology</i> , 2019, 30, iv57.	0.6	0

#	ARTICLE	IF	CITATIONS
649	Validation and refinement of PROSASH model using the neutrophil-to-lymphocyte ratio in patients with HCC receiving sorafenib. <i>Liver Cancer International</i> , 2020, 1, 6-11.	0.2	0
650	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. <i>Journal of Gastrointestinal Cancer</i> , 2021, , 1.	0.6	0
651	Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 9632-9632.	0.8	0
652	Adjuvant therapies in patients with colorectal cancer: An audit on clinical practice in Italy. <i>Journal of Clinical Oncology</i> , 2004, 22, 3648-3648.	0.8	0
653	A novel clinical-pathological score correlates with global outcome of locally advanced rectal cancer patients receiving neoadjuvant chemo-radiotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 3667-3667.	0.8	0
654	Efficacy and toxicity of a low dose regimen of capecitabine and oral vinorelbine. <i>Journal of Clinical Oncology</i> , 2008, 26, 12013-12013.	0.8	0
655	Nuclear factor- $\kappa$ B (NF- $\kappa$ B) predicts outcome in locally advanced rectal cancer patients receiving radio-chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 22122-22122.	0.8	0
656	Correlation of tumor integrins and peritoneal carcinosis capability of gastric cancer.. <i>Journal of Clinical Oncology</i> , 2010, 28, e14539-e14539.	0.8	0
657	Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. , 2010, , .		0
658	A novel approach to manage skin toxicity caused by cetuximab and panitumumab.. <i>Journal of Clinical Oncology</i> , 2011, 29, 616-616.	0.8	0
659	Palliative Treatment. , 2012, , 209-214.		0
660	Adjuvant Treatment After Surgical Resection. , 2012, , 187-194.		0
661	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib.. <i>Journal of Clinical Oncology</i> , 2012, 30, 380-380.	0.8	0
662	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. <i>Journal of Clinical Oncology</i> , 2012, 30, 449-449.	0.8	0
663	Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first-line matter?. <i>Journal of Clinical Oncology</i> , 2012, 30, e14663-e14663.	0.8	0
664	Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms and Clinical Outcome in Advanced Renal Cell Carcinoma Patients Receiving First Line Sunitinib. <i>Annals of Oncology</i> , 2012, 23, ix274.	0.6	0
665	Targeting Hedgehog in pancreatic cancer: An innovative approach but not for all tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 205-205.	0.8	0
666	Tumor cancer stem cell genetic profile as predictor of relapse in stage II and III radically resected colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 429-429.	0.8	0

#	ARTICLE	IF	CITATIONS
667	Locally advanced or metastatic pancreatic tumors: Molecular biology may help to know it and to select the optimal treatment.. Journal of Clinical Oncology, 2013, 31, 201-201.	0.8	0
668	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.. Journal of Clinical Oncology, 2013, 31, 208-208.	0.8	0
669	Correlation of KRAS mutational state with the expression of the hedgehog pathway in patients with pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 227-227.	0.8	0
670	Angiogenesis genotyping, LDH serum levels, and treatment efficacy for advanced hepatocellular carcinoma patients receiving sorafenib.. Journal of Clinical Oncology, 2014, 32, 245-245.	0.8	0
671	Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 474-474.	0.8	0
672	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 64-64.	0.8	0
673	Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC.. Journal of Clinical Oncology, 2014, 32, 474-474.	0.8	0
674	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 421-421.	0.8	0
675	WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE 5-FLUOROURACIL AND 6S-LEUCOVORIN AS A 2ND-LINE THERAPY IN ADVANCED COLORECTAL-CANCER RESISTANT TO A 5-FLUOROURACIL/6S-LEUCOVORIN BOLUS COMBINATION. Oncology Reports, 1995, 2, 377-9.	1.2	0
676	ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY. Oncology Reports, 1995, 2, 1033-5.	1.2	0
677	c-erbB-2 and common prognostic factors in breast cancer patients. Oncology Reports, 1996, 3, 883-6.	1.2	0
678	Measurements of cellular proliferation by H-3-thymidine-labeling index and flow cytometry in breast cancer patients. Oncology Reports, 1997, 4, 539-41.	1.2	0
679	High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer.. Journal of Clinical Oncology, 2014, 32, 4540-4540.	0.8	0
680	Pretreatment neutrophil to lymphocyte ratio may be an useful tool in predicting survival in early triple-negative breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 1111-1111.	0.8	0
681	Single-nucleotide polymorphisms (SNPs) associated with outcome: The first experience in thymic tumors.. Journal of Clinical Oncology, 2014, 32, e18557-e18557.	0.8	0
682	VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer?. Journal of Clinical Oncology, 2014, 32, 4533-4533.	0.8	0
683	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. Journal of Clinical Oncology, 2014, 32, e15563-e15563.	0.8	0
684	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1.. Journal of Clinical Oncology, 2014, 32, e15140-e15140.	0.8	0

#	ARTICLE	IF	CITATIONS
685	Abstract 2220: Impact of single-nucleotide polymorphisms (SNPs) on thymic hyperplasia and tumors outcome. , 2014, , .		0
686	Molecular selection for colorectal cancer (CRC) patients receiving cetuximab: Final results of a prospective study.. Journal of Clinical Oncology, 2015, 33, 596-596.	0.8	0
687	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy.. Journal of Clinical Oncology, 2015, 33, 313-313.	0.8	0
688	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology, 2015, 33, 705-705.	0.8	0
689	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2015, 33, 591-591.	0.8	0
690	FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. Journal of Clinical Oncology, 2015, 33, 372-372.	0.8	0
691	Angiogenic profile and pathological features in the prediction of clinical outcome of advanced renal cell carcinoma patients receiving sunitinib.. Journal of Clinical Oncology, 2015, 33, 458-458.	0.8	0
692	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: Preliminary results.. Journal of Clinical Oncology, 2015, 33, e13501-e13501.	0.8	0
693	Multigene profiling in incidentally- and clinically detected prostate cancer.. Journal of Clinical Oncology, 2015, 33, e16107-e16107.	0.8	0
694	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2015, 33, e15156-e15156.	0.8	0
695	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. Journal of Clinical Oncology, 2015, 33, e15595-e15595.	0.8	0
696	GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. Journal of Clinical Oncology, 2015, 33, 2054-2054.	0.8	0
697	Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 45-45.	0.8	0
698	Abstract 3401: Impact of VEGF and VEGFR polymorphisms on neuroendocrine tumors of the gastro-entero-pancreatic system (GEPNETs) outcome. , 2016, , .		0
699	Angiosuppression and chemotherapy: strategies aimed at their integration in cancer patients. International Journal of Biological Markers, 1999, 14, 239-42.	0.7	0
700	Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. Journal of Clinical Oncology, 2004, 22, 9632-9632.	0.8	0
701	Perioperative anemia as prognostic factor in patients undergoing resection for non-small cell lung cancer. Journal of Clinical Oncology, 2004, 22, 7179-7179.	0.8	0
702	The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. Tumori, 2013, 99, 122-4.	0.6	0



#	ARTICLE	IF	CITATIONS
703	Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. Tumori, 2011, 97, 449-53.	0.6	0
704	Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches?. Chinese Clinical Oncology, 2013, 2, 26.	0.4	0
705	Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and Clinical Outcomes in MSI-H population: The PROSECCO Study.. Journal of Clinical Oncology, 2022, 40, e16068-e16068.	0.8	0